One such combination involves cilofexor, an FXR agonist, and firsocostat, an ACC inhibitor, which has demonstrated promising results in reducing liver fat and improving liver enzymes in NASH patients (https://classic.clinicaltrials.gov/ct2/show/NCT02781584, accessed on 19 July 2023). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.